Mike Gibson, ASCO 2019 – KEYNOTE-062 and KEYNOTE-48 trial data
Editorial Board member, Mike Gibson, reviews data presented at the ASCO 2019 annual meeting around the immune checkpoint inhibitor, pembrolizumab, in the treatment of head and neck cancers. This includes a discussion around KEYNOTE-062 (NCT02494583) and KEYNOTE-48 (NCT02358031) data, the factors that influence the choice of pembrolizumab monotherapy vs pembrolizumab plus chemotherapy and the role biomarkers have in predicting response to pembrolizumab.
1. What were the efficacy and safety findings of the KEYNOTE-062 study in patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma? (0:04)
2. What were the findings of KEYNOTE-048 study in patients with recurrent/metastatic head and neck squamous cell carcinoma? (1:22)
3. What factors influence the choice of pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in these malignancies? (2:27)
4. What role do tumour mutational burden and other biomarkers play in predicting response to pembrolizumab? (3:11)
5. What further research is needed to optimise outcomes with pembrolizumab? (3:51)
Speaker disclosure: Mike Gibson has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Head and Neck Cancer
Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the […]
Jean-Pascal Machiels, ESMO 2022: Phase 3 KEYNOTE-412 study – efficacy and safety of pembrolizumab + chemoradiation therapy in locally advanced head and neck squamous cell carcinoma
Pembrolizumab is currently approved as monotherapy or in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss the current limitations in treatment options, and the phase 3 KEYNOTE-412 study investigating the efficacy and safety of pembrolizumab + chemoradiation therapy (CRT) vs […]
Jean-Pascal Machiels, ESMO 2022: Highlights in head and neck cancer
Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022. Questions: What are the hot topics and highlights in head and neck cancers from ESMO 2022? Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!